Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Polyclonal Antibodies Industry?

The market size for polyclonal antibodies has seen consistent growth over the past few years. Its value is projected to rise from $1.41 billion in 2024 to $1.48 billion in 2025, signifying a compound annual growth rate (CAGR) of 5.0%. The expansion during the historic period is due to factors such as the demand for biomedical research, the rise in diagnostic applications, growing incidence of chronic illnesses, and their versatile applications.

In the upcoming years, the polyclonal antibodies market is predicted to experience a significant surge in size. The market is projected to swell to “$1.94 billion by 2029, progressing at a compound annual growth rate (CAGR) of 6.9%. This projected upturn during the forecast period can be ascribed to the growth in diagnostic technologies, progress in therapeutic methods, a surge in infectious diseases, heightened research sponsorships, and synergies. Key trends in this forecast timeline consist of improvements in antibody engineering, an increasing impact on cancer immunotherapy, the emergence of biosimilar polyclonal antibodies, its utilization in treating neurological disorders, and regulatory progress and adherence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10790&type=smp

#Which Factors Are Currently Driving The Growth Of The Polyclonal Antibodies Market?

The rising incidence of cancer is likely to stimulate the expansion of the polyclonal antibodies market in the future. These antibodies play a crucial role in cancer research and treatment by facilitating biomarker recognition, immunohistochemistry, targeted therapy, and immunotherapy, which enhance cancer diagnosis and treatment, thus leading to improved patient outcomes. The surge in cancer patients is a significant contributor to the expansion of the polyclonal antibodies market. For instance, Cancer Australia, an Australian organization that supports cancer patients and raises disease awareness throughout Australia and its territories, reported in September 2022, that 2,572 new cases of stomach cancer (1,661 in men and 911 in women) are anticipated to be diagnosed in 2022. By the time individuals reach the age of 85 in 2022, they face a 1 in 114 (or 0.87%) risk of developing stomach cancer (1 in 1.1 or 87% for men and 1 in 167 or 0.60% for women). Thus, the growing incidence of cancer is a significant driver of the polyclonal antibodies market’s growth.

The polyclonal antibodies market covered in this report is segmented –

1) By Product Type: Primary Antibody, Secondary Antibody

2) By Source: Rabbits, Goats, Sheep, Other Sources

3) By Application: Research, Diagnostics, Therapy

4) By End-User: Academic and Research Center , Pharmaceutical and Biotechnology Companies, Diagnostic Centers , Hospitals

Subsegments:

1) By Primary Antibody: Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), Immunoglobulin E (IgE)

2) By Secondary Antibody: Anti-Mouse IgG, Anti-Rabbit IgG, Anti-Goat IgG, Other Secondary Antibodies

How Are Key Trends Driving Expansion In The Polyclonal Antibodies Industry?

In the polyclonal antibodies market, research and development are emerging as significant trends. To enhance their observational abilities and maintain their market share, prominent companies in the polyclonal antibodies landscape are investing in R&D. For example, in July 2022, the American biotech firm GigaGen Inc., published a research study titled ‘GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,’ in the international journal, Pathogens. The study introduced GigaGen’s recombinant polyclonal product GIGA-2050, which targets SARS-CoV-2, and discussed its GMP production and IND-enabling research on their new category of drugs, recombinant polyclonal antibodies. Comprising more than 12,000 antibodies from a single master cell bank (MCB), GIGA-2050 is a considerable advancement from previous, smaller recombinant antibody mixes that necessitated individual MCBs for each monoclonal antibody, which were then combined before production.

Who Are The Main Participants Shaping The Polyclonal Antibodies Market Landscape?

Major companies operating in the polyclonal antibodies market include Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., Illumia Inc., ImmonoPresice Antibodies Ltd, Fujirebio, Omega BioTek Inc., Dovetail Genomics LLC, Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Which Region Currently Holds The Largest Share In The Polyclonal Antibodies Market?

North America was the largest region in the polyclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10790&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model